Title
Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats.

Permalink
https://escholarship.org/uc/item/5hg9t252

Journal
American journal of physiology. Regulatory, integrative and comparative physiology, 308(10)

ISSN
0363-6119

Authors
Javkhedkar, Apurva A
Quiroz, Yasmir
Rodriguez-Iturbe, Bernardo
et al.

Publication Date
2015-05-01

DOI
10.1152/ajpregu.00308.2014

Peer reviewed
Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats

Apurva A. Javkhedkar,1 Yasmir Quiroz,2 Bernardo Rodriguez-Iturbe,2 Nosratola D. Vaziri,3 Mustafa F. Lokhandwala,1 and Anees A. Banday1

1Heart and Kidney Institute, College of Pharmacy, University of Houston, Houston Texas; 2Hospital Universitario, Universidad del Zulia and Instituto Venezolano de Investigaciones Cientificas-Zulia, Maracaibo, Venezuela; and 3Division of Nephrology and Hypertension, University of California, Irvine, California

Submitted 18 July 2014; accepted in final form 6 March 2015

Am J Physiol Regul Integr Comp Physiol 308: R840–R846, 2015. First published March 11, 2015; doi:10.1152/ajpregu.00308.2014.—Compelling evidence supports the role of oxidative stress and renal interstitial inflammation in the pathogenesis of hypertension. Resveratrol is a polyphenolic stilbene, which can lower oxidative stress by activating the transcription factor nuclear factor-E2-related factor-2 (Nrf2), the master regulator of numerous genes encoding antioxidant and phase II-detoxifying enzymes and molecules. Given the role of oxidative stress and inflammation in the pathogenesis of hypertension, we conducted this study to test the hypothesis that long-term administration of resveratrol will attenuate renal inflammation and oxidative stress and, hence, progression of hypertension in the young spontaneously hypertensive rats (SHR). SHR and control [Wistar-Kyoto (WKY)] rats were treated for 9 wk with resveratrol or vehicle in their drinking water. Vehicle-treated SHR exhibited renal inflammatory injury and oxidative stress, as evidenced by glomerulosclerosis, tubulointerstitial injury, infiltration of inflammatory cells, and increased levels of renal 8-isoprostanate and protein carbonylation. This was associated with reduced antioxidant capacity and deregulations of Nrf2 and phase II antioxidant enzyme glutathione-S-transferase (GST). Resveratrol treatment mitigated renal inflammation and injury, reduced oxidative stress, normalized antioxidant capacity, restored Nrf2 and GST activity, and attenuated the progression of hypertension in SHR. However, resveratrol had no effect on these parameters in WKY rats. In conclusion, development and progression of hypertension in the SHR are associated with inflammation, oxidative stress, and impaired Nrf2-GST activity in the kidney. Long-term administration of resveratrol restores Nrf2 expression, ameliorates inflammation, and attenuates development of hypertension in SHR. Clinical studies are needed to explore efficacy of resveratrol in human hypertension.

Oxidative Stress is a condition in which generation of reactive oxygen species (ROS) exceeds the capacity of the antioxidant defense system. ROS triggers inflammation, which confounds the deleterious effects of oxidative stress. In renal and vascular tissues, oxidative stress and its constant companion inflammation play a major role in the pathogenesis of all forms of hypertension by complex mechanisms that involve ROS-mediated inactivation and reduced production of NO, generation of vasoconstrictive prostanoids, augmentation of sympathetic activity, and sodium retention (31). Numerous studies have demonstrated increased production of ROS, upregulation of ROS-generating enzymes, and accumulation of biomarkers of oxidative stress in the kidney and vascular tissues of animals with acquired and genetic hypertension (23). Under normal conditions, nuclear factor-erythroid-2-related factor 2 (Nrf2) plays a central role in basal activity and coordinated induction of more than 250 genes, including those encoding antioxidant and phase II-detoxifying enzymes and substrates (13, 32). Thus, impaired activation of Nrf2 can contribute to the development or amplification of oxidative stress, and inflammation and strategies aimed at restoration of Nrf2 activity should help to contain these pathological conditions and their adverse consequences in hypertensive states.

Resveratrol is a polyphenolic stilbene derivative (3,4’,5-trihydroxy-trans-stilbene) found in several edible plants and in red wine that has received considerable attention because of its accessibility to the general population and a myriad of potential health benefits (18). Resveratrol has been found to counteract proinflammatory cytokines and improve chemically induced inflammation and confer numerous salutary effects (30). Nevertheless, most of these effects have not been confirmed in rigorous studies (5).

With respect to the beneficial cardiovascular effects of resveratrol, animal studies have shown amelioration of endothelial dysfunction and arteriolar remodeling (3, 28). These protective effects are largely mediated by its ability to activate Nrf2 and, hence, upregulate endogenous production of antioxidant and cytoprotective enzymes and substrates that attenuate oxidative stress and inflammation (29). Experimental and human studies have provided strong support for the role of renal inflammation in the pathogenesis of hypertension (11, 20, 21, 25). The complex interaction between immune cell infiltration, inflammatory cytokines, oxidative stress, and intrarenal ANG II raise the blood pressure, in part, by blunting pressure natriuresis (9). Resveratrol has been shown to ameliorate hypertension in double transgenic rats harboring human renin and human angiotensinogen genes (27), in estradiol-induced overproduction of superoxide in the rostral ventrolateral medulla, in animals with DOCA-salt hypertension, in obese Zucker rats, and in fructose-fed rats (4, 6, 16, 19). In addition, resveratrol has been reported to ameliorate hypertension, improve compliance and remodeling of the small arteries, and prevent development of pathological cardiac hypertrophy and contractile dysfunction in the spontaneously hypertensive rats (SHR) (3, 22, 28). To our knowledge, the effect of resveratrol on renal inflammation in SHR has not been previously demonstrated. The present study was undertaken to determine the
protective effects of resveratrol against renal inflammation, oxidative stress, and development of hypertension in the SHR.

**MATERIALS AND METHODS**

Male 3–4-wk-old spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) rats were purchased from Charles River Laboratories (Wilmington, MA) and kept in institutional facilities with free access to tap water and standard rat chow (Purina Mills, St. Louis, MO). All experiments were performed according to University of Houston guidelines and protocols and were approved by the Institutional Animal Care and Use Committee.

SHR and WKY rats were randomly divided into groups receiving either resveratrol (R) (50 mg/kg) or tap water. Resveratrol was prepared by first dissolving 50 mg resveratrol in 1 ml ethanol. This solution was then diluted with tap water (4). Rats were supplied with either fresh solution of resveratrol (SHR-R and WKY-R; n = 8–12 each) or tap water (SHR and WKY; n = 8–12 each) every day starting at 3–4 wk of age and maintained until 12 wk of age.

**Animal surgery.** Blood pressure was determined in unrestrained conscious animals by radiotelemetry. Sensor radio transmitters (TA11PA-C40; Data Sciences International, St. Paul, MN) were implanted in the aorta at 6 wk of age with sterile precautions under general 5% isoflurane anesthesia. To secure the catheter to the aorta, tissue adhesive (Vetbond, 3M Animal Care Products, St. Paul, MN) was used. The body of the telemetric device was placed in the abdominal cavity and sutured to the abdominal musculature. Postsurgical analgesia was achieved by the administration of buprenorphine (0.05 mg/kg sc) every 12 h for 2 days. Animals were allowed 1 wk for recovery before blood pressure measurements were recorded.

**Proximal tubule preparation.** Rats were anesthetized with pentobarbital sodium (50 mg/kg ip), and a midline abdominal incision was made to cannulate the aorta below the kidneys and initiate an in situ digestion with iso-osmotic collagenase and hyaluronidase (Sigma, St. Louis, MO). Density gradient centrifugation with 25% Ficoll in Krebs-Henseleit buffer was used to enrich and purify proximal tubules, as detailed previously (2). Proximal tubules were homogenized by routine lab methods, as detailed elsewhere (2), and protein concentration was determined by using a BCA kit with BSA as a standard.

**Measurement of oxidative and antioxidative markers.** Oxidative markers like renal proximal tubular 8-isoprostane and protein carbonylation (Millipore, Billerica, MA) were measured by using commercially available assay kits. Renal proximal tubular antioxidant capacity and the activities of antioxidative enzymes glutathione-S-transferase (GST) and superoxide dismutase (SOD) were measured by using commercially available kits from Cayman Chemicals (Ann Arbor, MI).

**Immunoblotting.** Renal proximal tubular homogenate and nuclear fractions for GST and Nrf2, respectively, were resolved by SDS-PAGE and transferred to PVDF membrane (Millipore, Bedford, MA) followed by overnight blocking with 5% BSA (Pierce, Rockford, IL). The membranes were incubated with anti-GST rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-Nrf2 antibody (Ab53019; AbCam, Cambridge, MA), and Western blot analysis was performed as detailed previously (1).

**Light microscopy and immunohistochemistry.** Rats were killed by exsanguination under general anesthesia, and kidneys were harvested for light microscopy and immunohistochemistry studies. Light microscopy was done in the formalin-fixed sections stained with periodic acid-Schiff and hematoxylin and eosin. Glomerulosclerosis index score and tubulointerstitial damage were evaluated as described in previous studies (17–19). The sclerosis in the glomeruli were graded from 0 to +4: grade 0 = normal, grade +1 = <25% involvement of the glomerular tuft, grade +2 = 25–50% involvement of the glomerular tuft, grade +3 = 50–75% involvement of the glomerular tuft, and grade +4 = sclerosis occupying >75% of the glomerular tuft. The glomerulosclerosis score was obtained as follows: \((1 \times n \text{ glomeruli with } +1) + (2 \times n \text{ glomeruli with } +2) + (3 \times n \text{ glomeruli with } +3) + (4 \times n \text{ glomeruli with } +4)\) \times 100/total number of glomeruli examined. Tubulointerstitium was evaluated in successive fields examined at \(\times 20\) magnification in the entire cortical and juxtamedullary areas of each specimen using computer-assisted image analysis (Olympus BX51 System Microscope and DP70 microscope digital camera with software, Sigma Pro, Leesburg, VA). Tubulointerstitial damage (tubular dilation, interstitial infiltration, and fibrosis) was graded in a 0–5 scale: 0 = no changes, grade 1 = <10%, grade 2 = 10–25%, grade 3 = 25–50%, grade 4 = 50–75%, grade 5 = 75–100%. Immunoperoxidase methodology was used to identify lymphocytes and macrophages in the glomeruli (positive cells/glomerular cross section) and tubulointerstitial regions (positive cells per mm2). All histological evaluations were done without prior knowledge of the experimental group being studied.

**Antisera for immunohistochemistry.** Macrophages were identified with mouse anti-ED1 (Biosource, Camarillo, CA), lymphocytes with mouse anti-rat CD5 (Biosource) and ANG II-positive cells with rabbit anti-ANG II-human IgG (Peninsula Laboratories). Peroxidase-conjugated goat anti-mouse IgG (Stressgen Bioreagents Victoria, BC Canada) was used as a secondary antibody.

**Nrf2 assay.** Nuclear Nrf2 translocation was determined by following the protocol described by Wang et al. (33, 34). Briefly, Nrf2 double-stranded DNA probe was commercially synthesized by using the published ARE sequence. Strand one was labeled at 5′ end with 6-FAMTM Fluorescein fluorophore and the complementary strand was labeled at 3′ end with Iowa Black FQ, a quencher. A single-stranded DNA competitor with sequence similar to quencher sequence was synthesized as well. The binding of Nrf2 to double-stranded ARF sequence stabilized the fluorophore-quencher complex and delayed the competitor from separating from the fluorophore. Therefore, the higher the Nrf2 content, the lower the fluorescence intensity, allowing quantitative measurement of Nrf2 protein concentration based on its inverse relation to the fluorescence intensity. Proximal tubular nuclear fractions, isolated by using commercially NE-PER extraction kit (Thermo Fisher), was incubated with double-stranded ARE sequence in the presence and absence of competitor single-stranded sequence as detailed by Wang et al. (33). Fluorescence was measured by BioTek plate reader (absorption 495/emission 520).

**Statistical analysis.** Results are presented as means ± SE. Two-way ANOVA with Newman-Keuls post hoc tests were used for evaluation of statistical significance of difference between means. \(P < 0.05\) was considered significant. Commercially available statistical software (GraphPad Prism, version 5, San Diego, CA) was used for analysis.

**RESULTS**

**Effect of resveratrol on body weight, food and water intake, and blood pressure.** Resveratrol treatment was started at the age of 3 wk and continued until 12 wk of age. Blood pressure measurements were recorded from the age of 7–12 wk. Body weight (g, WKY: 312.3 ± 5.1, WKY-R: 318.8 ± 5.1, SHR: 327.5 ± 8.1, SHR-R: 316.3 ± 9.2), food consumption (g/day, WKY: 19.3 ± 3.7, WKY-R: 17.5 ± 3.4, SHR: 21.1 ± 4.7, SHR-R: 20.5 ± 3.0) and water intake (ml/day, WKY: 46.0 ± 6.3, WKY-R: 47.3 ± 5.1, SHR: 42.8 ± 6.1, SHR-R: 47.3 ± 5.8) were similar in all the experimental groups. As expected, the mean arterial pressure was significantly higher in SHR compared with WKY rats (Fig. 1). Compared with untreated SHR, resveratrol-treated SHR showed a significant reduction in blood pressure from week 9 onward (Fig. 1). Moreover, unlike the untreated SHR, which showed a steady rise in blood pressure, the resveratrol-treated group showed no further rise...
in blood pressure beyond 7 wk of age. Untreated and resveratrol-treated WKY showed similar MAP (Fig. 1).

Effect of resveratrol on markers of oxidative stress and antioxidant capacity. The renal proximal tubular 8-isoprostane level was significantly higher in SHR compared with WKY rats (Fig. 2A). Resveratrol treatment significantly decreased proximal tubular 8-isoprostane levels in SHR, while having no effect in WKY rats (Fig. 2A). Also, proximal tubular protein carbonyl levels were significantly higher in SHR compared with WKY rats (Fig. 2B). Resveratrol treatment significantly decreased protein carbonyl levels in SHR but not in WKY rats (Fig. 2B). Proximal tubular total antioxidant activity was significantly lower in SHR than in WKY rats (Fig. 2C). Resveratrol treatment restored total antioxidant activity in SHR, while having no effect in WKY rats (Fig. 2C).

Effect of resveratrol on renal injury and inflammation. Both treated and untreated SHR groups exhibited mild, but significant, increments in the glomerulosclerosis index (scores: WKY: 4.0 ± 0.65, SHR: 7.1 ± 1.37**, WKY-R: 4.1 ± 0.78, SHR-R: 6.2 ± 0.77*; **P < 0.01 vs. WKY, *P < 0.05 vs. WKY), and tubulointerstitial injury (scores: WKY: 1.28 ± 0.48, SHR: 2.12 ± 0.33**, WKY-R: 1.11 ± 0.11, SHR-R: 1.89 ± 0.06*; **P < 0.01 vs. WKY, *P < 0.05 vs. WKY) compared with the corresponding values in the WKY rats. Resveratrol treatment did not modify renal histology in the WKY rats but led to a minor improvement in renal lesions in SHR. However, the difference between SHR and SHR-R did not reach the statistical significance.

Immune cells were rarely present in the glomeruli in any experimental group (<3 cells/glomerular cross section). In contrast, tubulointerstitial areas showed significant infiltration of inflammatory cells. Resveratrol treatment ameliorated the renal infiltration of lymphocytes, macrophages, and ANG II-positive cells in tubulointerstitial areas of the kidney (Fig. 3, A–C and microphotographs in Fig. 4).

Effect of resveratrol on Nrf2 activity and its downstream antioxidant enzymes. As shown in Fig. 5A, the fluorescence intensity was higher in SHR proximal tubular nuclear extracts, suggesting a decrease in Nrf2 concentration as fluorescence intensity is inversely proportional to Nrf2 concentration. The decrease in nuclear Nrf2 was also observed with Western blot analysis, as Nrf2 immunoreactivity was significantly lower in SHR compared with WKY rats (Fig. 5, B and C). Resveratrol treatment significantly increased nuclear Nrf2 expression in the proximal tubules of SHR but had no effect in WKY rats (Fig. 5, A–C). GST message level, abundance, and activity were significantly lower in the proximal tubules of SHR compared with WKY rats, and resveratrol treatment normalized GST function in SHR (Fig. 6, A–C). Despite the presence of oxidative stress, SOD activity in SHR was similar to those found in the WKY, pointing to a maladaptive response in the SHR kidney (Fig. 6D). Resveratrol administration significantly increased SOD activity in SHR (Fig. 6D). Resveratrol had no effect on GST and SOD activity or expression in WKY rats (Fig. 6, A–D).

DISCUSSION

In confirmation of earlier studies, the untreated SHR exhibited interstitial immune cell infiltration in the renal tissue (22, 24). This was associated with marked elevation of by-products of lipid and protein oxidation in the isolated renal proximal tubular epithelial cells, suggesting oxidative stress in these cells. The present study demonstrated, for the first time, involvement of proximal tubular epithelial cells in this pathologic process. This is not surprising since proximal tubular epithelial cells are very rich in mitochondria, which generate massive amounts of ATP to accommodate reabsorption of filtered sodium by the Na+/K+-ATPase pump. Since mitochondria are the main source of ROS production, the antioxidant defense system is critical for proper functioning and viability of proximal tubular epithelial cells. Despite the presence of oxidative stress, which should have led to activation

Fig. 1. Effect of resveratrol (R) on blood pressure in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats. Blood pressure was measured continuously from 7 to 12 wk of age. Data are expressed as means ± SE from 6–8 rats. *P < 0.05 vs. untreated SHR at respective time point.

Fig. 2. Effect of resveratrol (R) on oxidative stress in renal proximal tubules from SHR and WKY rats. Proximal tubular 8-isoprostane (A), protein carbonylation (B) and total antioxidant activity (C). Data are expressed as means ± SE from 6–8 rats. *P < 0.05 vs. WKY rats and #P < 0.05 vs. SHR.
(nuclear translocation) of Nrf2, the untreated SHR paradoxically exhibited a significant reduction of nuclear Nrf2 and diminished or unchanged expression of its target gene products in the proximal tubular epithelial cells. These findings point to the role of impaired Nrf2 activity in the pathogenesis of oxidative stress and inflammation in the SHR kidney.

The central findings of this study are the demonstration that early treatment with the natural Nrf2 activator, resveratrol, reduced oxidative stress in proximal tubular epithelial cells, lowered the number of interstitial inflammatory cells and ANG II-positive cells in the kidney, and attenuated progression of hypertension in SHR. Attenuation of oxidative stress in the proximal tubular epithelial cells with resveratrol administration was accompanied by and, in part, due to restoration of the Nrf2 activity, and expression of the antioxidant enzymes in the treated SHR. Previous studies have shown that one of the mechanisms of antioxidant effect of resveratrol is via activation of transcription factor Nrf2. Normally, ROS trigger activation (nuclear translocation) of the redox-sensitive transcription factor Nrf2, which leads to transcriptional upregulation of numerous target genes encoding detoxifying and antioxidant enzymes and related proteins (15). Despite the presence of oxidative stress, Nrf2 activation was significantly lower in the SHR kidney compared with the WKY rats. Resveratrol treatment caused a significant increase in nuclear Nrf2 abundance in the proximal tubular epithelial cells of the SHR group. It is

Fig. 3. Effect of resveratrol (R) on kidney tubulointerstitial inflammation in SHR and WKY rats. Lymphocytes: CD5⁺ cells (A), macrophages: CD68⁺ cells (B), and ANG II-positive cells (C) are all increased in the SHR and reduced by resveratrol treatment. Data are expressed as means ± SE. *P < 0.05 vs. WKY rats and #P < 0.05 vs. SHR.

Fig. 4. Representative kidney microphotographs of the histologic (periodic acid-Schiff staining, row 1), (hematoxylin-and-eosin staining, row 2) and immunohistologic findings (immunoperoxidase; rows 3 and 4) in WKY, SHR treated with resveratrol (SHR-R) and SHR. Light histology is normal in WKY rats and show focal areas of tubular dilation and atrophy in the SHR-R, while SHR rats (untreated) show more extensive tubulointerstitial damage and one glomerulus with a focal (<10%) are of sclerosis. ANG II-positive cells (row 3) are not found in the WKY rats, a small number of tubular cells stain positive for ANG II (arrows) in the SHR-R group and are increased in number, in association with positive infiltrating cells in the SHR control. Lymphocytes (row 4) are scarce in the WKY group and are increased in number in the SHR-R group, and higher numbers of lymphocytes are present in the SHR group.
noteworthy that resveratrol treatment did not alter the constitutive activity of Nrf2 in the WKY rats, reflecting their ability to maintain redox homeostasis.

Nrf2-mediated activation of antioxidant enzymes, such as GST and SOD, plays an important role in protecting the cells against oxidative injury and in the aging process (10). We found that GST protein expression and activity was significantly decreased in proximal tubules of SHR, and resveratrol treatment normalized both abundance and activity of GST in these rats. Despite oxidative stress, proximal tubular SOD activity in the SHR was similar to those found in the WKY rats, indicating failure of these rats to counter increased oxidative stress. Long-term resveratrol administration enhanced SOD and GST levels in the SHR but not in the WKY rats. Taken together, these findings illustrate the role of impaired Nrf2 activity in the pathogenesis of oxidative stress in the proximal tubular epithelial cells of SHR and its amelioration with long-term administration of resveratrol.

Oxidative stress, renal interstitial inflammation, and activation of intrarenal ANG II are intimately interrelated and participate in a vicious cycle, which promotes hypertension by augmenting vascular resistance and reducing pressure natriuresis (9, 31). Therefore, it is not surprising that amelioration of oxidative stress with resveratrol administration resulted in the reduction of renal inflammation and intrarenal ANG II expression and lowering of blood pressure in SHR. The suppression of renal inflammation obtained with resveratrol has been previously shown in experimental models of obesity, diabetes, monocrotaline-induced pulmonary hypertension and ANG II-induced hypertension (6, 7, 12, 14, 17, 26, 35). Although we did not study renal ANG II activity, we found that increased ANG II-positive cells in the untreated SHR kidney tissue,

---

**Fig. 5.** Effect of resveratrol (R) on nuclear Nrf2 expression in renal proximal tubules form SHR and WKY rats. Nrf2 nuclear fluorescence intensity (A), bars representing nuclear Nrf2 immunoreactivity (B), and three representative nuclear Nrf2 blots and a histone blot. lane 1, WKY; lane 2, SHR; lane 3, WKY-R; lane 4, SHR-R (C). MW, molecular weight; V, vehicle. Data are expressed as means ± SE from 6–8 rats. *P < 0.05 vs. WKY rats, and #P < 0.05 vs. SHR.

---

**Fig. 6.** Effect of resveratrol (R) phase II antioxidant enzymes in renal proximal tubules form SHR and WKY rats. A: glutathione-S-transferase (GST) protein mRNA level. B: bars representing protein content; top: a representative immunoblot: lane 1, WKY; lane 2, SHR; lane 3, WKY-R; and lane 4, SHR-R. Enzymatic activity of GST (C) and superoxide dismutase (SOD) in proximal tubules (D). Data are expressed as means ± SE from 6–8 rats. *P < 0.05 vs. WKY rats, and #P < 0.05 vs. SHR.
which were reduced by resveratrol treatment. Previous studies from our laboratories have shown that in tubulointerstitial inflammation, the fluctuations of ANG II-positive cells are directly correlated with the existing renal ANG II activity (8).

Limitations. Although resveratrol treatment, in part, via Nrf2 signaling, ameliorated renal oxidative stress and inflammation, the blood pressure in SHR remained significantly higher than WKY rats. This is not surprising given the fact that hypertension is a multifactorial disease. While renal oxidative stress and inflammation are major contributors to etiology of hypertension, many other organs via a plethora of mechanisms also significantly contribute to the development and maintenance of long-term high blood pressure.

Perspectives and Significance

The development and progression of hypertension in the young SHR are associated with impaired Nrf2 signaling, inflammation, and oxidative stress in renal proximal tubular epithelial cells. Long-term administration of resveratrol, a natural Nrf2 activator, restores Nrf2 activity, improves oxidative milieu and inflammation, and attenuates severity and progression of hypertension in SHR. Further studies are needed to explore the effects resveratrol as an adjunct in the treatment of hypertension in humans.

GRANTS

The study was supported by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-098509 to M. F. Lokhandwala, a Scientist Development Grant (0835142SN, National Center) from the American Heart Association to A. A. Banday, and Grant FONACYT-LOCTI 1306 to B. Rodriguez-Iturbe.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

Author contributions: A.A.J. and Y.Q. performed experiments; A.A.J. and Y.Q. analyzed data; A.A.J. and Y.Q. interpreted results of experiments; A.A.J. and Y.Q. prepared figures; A.A.J. and N.D.V. drafted manuscript; A.A.J., Y.Q. analyzed data; A.A.J. and Y.Q. interpreted results of experiments; A.A.J. wrote the manuscript.

REFERENCES


